









Markets
/
Stocks
/
nasdaq-sybx
/

Synlogic Inc

SYBX

1.780USD

+0.110+6.59%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

20.82MMarket Cap

LossP/E TTM



Synlogic Inc

1.780

+0.110+6.59%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . The company shows very weak stock market performance, in line with its fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

254 / 506

Overall Ranking

413 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

1.000

Target Price

-16.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. It designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.

Growing

The company is in a growing phase, with the latest annual income totaling USD 8.00K.

Undervalued

The company’s latest PE is -21.95, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 8.87M shares, decreasing 4.39% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 183.00K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.69, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.69

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

2.36

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.69

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.36

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -20.59, which is -98.69% below the recent high of -0.27 and 96.62% above the recent low of -0.70.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 254/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03. The average price target for Synlogic Inc is 1.00, with a high of 1.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.79, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.83 and the support level at 1.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.79

Change

0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.058

Buy

RSI(14)

71.130

Buy

STOCH(KDJ)(9,3,3)

88.187

Overbought

ATR(14)

0.083

High Vlolatility

CCI(14)

119.161

Buy

Williams %R

0.000

Overbought

TRIX(12,20)

0.551

Sell

StochRSI(14)

67.987

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.709

Buy

MA10

1.604

Buy

MA20

1.533

Buy

MA50

1.503

Buy

MA100

1.342

Buy

MA200

1.333

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 75.82%, representing a quarter-over-quarter increase of 0.23%. The largest institutional shareholder is The Vanguard, holding a total of 183.00K shares, representing 1.56% of shares outstanding, with 0.02% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Cable Car Capital LLC

3.31M

New Enterprise Associates (NEA)

2.92M

Radoff (Bradley Louis)

629.21K

Armistice Capital LLC

614.29K

Kryzanowski (John A)

592.57K

-32.18%

The Vanguard Group, Inc.

Star Investors

183.00K

Atlas Venture

176.80K

Fidelity Management & Research Company LLC

160.18K

Geode Capital Management, L.L.C.

66.24K

-3.22%

Awad (Antoine)

29.57K

-12.68%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.73, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.54. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.